Friends! My book WRONGED: THE WEAPONIZATION OF VICTIMHOOD is now available: cup.columbia.edu/book/wronged/9… Columbia Univ Press

New paper by Michael Anderson & colleagues.

It suggests that previous evidence indicating that private hospitals provide a higher quality of care compared to NHS hospitals may potentially overlook unobserved confounding at the patient-level.

sciencedirect.com/science/articl…

🆕Dr Leeza Osipenko Consilium Scientific, Iva Parvanova, Professor Elias Mossialos & colleagues' new paper analyses the origin & clinical benefits of first-in-class drugs.

🔗Read more about their findings here ➡ lnkd.in/e9sazGqc

As #PHSSR EU Expert Advisory Group co-chair, I hosted an event in @EuroParl_EN, where we launched report dedicated to key policy recommendations on prevention&early detection of #NCDs in 🇪🇺. I want to thank co-chair Elias Mossialos and other experts for their invaluable contributions.

New book out with Columbia Univ Press May 2024!

What is the provenance of medicines that entered France between 2008-2018 and what clinical benefit do they deliver❓Latest paper JAMA Internal Medicine by Leeza Osipenko Consilium Scientific Alexandra Kupryjanczuk, Alexandra Schuster, Bernardo Perez Elias Mossialos et al.⬇️bit.ly/3MQYmPB

Huge congratulations to
SangJune Kim for passing his PhD viva today! He made Elias Mossialos and me very proud supervisors. We are thrilled about the outcome and process. Many thanks to Panos Kanavos and Soonman Kwon for examining LSE Health Policy 🍾

Analysis of 632 medications introduced to the French market between 2008-2018 found that approx 1 in 4 drugs originated in the academic setting. Medicines originating in academia were more likely to be characterized as providing added clinical benefit. ja.ma/3QKP4FP

Utterly heartbreaking. Nobody knows a person better than a parent or a close relative. They must be listened to as an equal member of the clinical team. There are so many lessons for individual doctors, clinical teams, and health systems to learn from the life of Martha Mills.

LSE Executive MSc Healthcare Decision-Making, in collaboration with NICE

Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model frontiersin.org/articles/10.33…

Antibiotic resistance is one of the world’s biggest challenges today.

Read this new Health Policy on challenges & opportunities for incentivising antibiotic research & development in Europe.

Dimitra Panteli, Elias Mossialos Robin van Kessel, PhD Francesca Colombo

thelancet.com/journals/lanep…

How can the EU support sustainable innovation 🌍 and access to effective antibiotics? 💊

New policy brief from European Observatory on Health Systems & Policies with LSE Health Policy authors Michael Anderson and Elias Mossialos available now 📑 ow.ly/9Vi250OTywc

Job Opportunity

Assistant Professor in Health Policy

At the LSE Health Policy Department (@LSEnews)

To join a great department with Clare Wenham 🌈 Andrew Street 🇪🇺 Dr. Mylene Lagarde Joan Costa-Font (he/him)🌏 Ranjeeta Thomas Panos Kanavos Elias Mossialos Emilie Courtin Rocco Friebel

jobs.lse.ac.uk/Vacancies/W/20…

📣 Transplant International #PoweredByESOT
A new framework and case studies have been released, showcasing the key features of successful organ donation & transplantation systems.
Vassilios Papalois Elias Mossialos Patrick Jeurissen, Chloe Balleste, John Forsythe

go.esot.org/ti_si_maxpot

Thrilled Omar Al-Ghazzi and my “Beyond Verification: Flesh witnessing and the significance of embodiment in conflict news” got an Honourable Mention at Journalism Studies / ICA. 🙏 to the committee and Journalism editors Barbie Zelizer, H. Tumber. LSE Media & Communications #ica23

Health systems. Environmental sustainability. The #climatecrisis .

They’re all linked. But exactly how they are may surprise you.

⁦WHO/Europe⁩ and ⁦European Observatory on Health Systems & Policies⁩ colleagues join me in explaining this connection for ⁦The Lancet⁩. thelancet.com/journals/lance…

'The UK must establish safeguards that prevent the MHRA from automatically following questionable approvals from other regulators'

Avi Cherla and colleagues write that the MHRA's new regulatory model must prioritise safety and efficacy over speed
bmj.com/content/381/bm…

Our critique of AI systems should not focus on an imaginary dystopia of “powerful digital minds” but the very real and very present exploitative practices of the companies that build them, as they rapidly centralise power and increase social inequalities👇